menu
    • menu

    Company profile for Concert Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Concert Pharmaceuticals, we are pioneering the use of deuterium chemistry to discover and develop innovative new medicines that positively impact patient care and address important medical needs. Each of these novel candidates is a result of improving a drug using our deuterium chemistry, expanding the potential of a previously studied or approved drug.Our robust pipeline of new medicines is rapidly advancing to offer innov...
    At Concert Pharmaceuticals, we are pioneering the use of deuterium chemistry to discover and develop innovative new medicines that positively impact patient care and address important medical needs. Each of these novel candidates is a result of improving a drug using our deuterium chemistry, expanding the potential of a previously studied or approved drug.Our robust pipeline of new medicines is rapidly advancing to offer innovative ways to treat a broad range of disease areas, targeting autoimmune and inflammatory diseases and central nervous system (CNS) disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Concert PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    99 Hayden Avenue, Suite 500 Lexington, MA 02421
    Telephone
    Telephone
    + 781-860-0045
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.concertpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/concert-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Phase 3 Data at AAD 2023 Show Deuruxolitinib Improved Scalp Hair Regrowth
    Phase 3 Data at AAD 2023 Show Deuruxolitinib Improved Scalp Hair Regrowth

    18 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/late-breaking-phase-3-data-at-aad-2023-show-oral-investigational-medicine-deuruxolitinib-significantly-improved-scalp-hair-regrowth-in-alopecia-areata-301775606.html

    PR NEWSWIRE
    18 Mar 2023
    Share Share
    Sun Pharma Completes Acquisition of Concert Pharmaceuticals
    Sun Pharma Completes Acquisition of Concert Pharmaceuticals

    07 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sun-pharma-completes-acquisition-of-concert-pharmaceuticals-301763327.html

    PR NEWSWIRE
    07 Mar 2023
    Share Share
    Concert Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA
    Concert Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA

    15 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230215005147/en

    BUSINESSWIRE
    15 Feb 2023
    Share Share
    Concert persuades FDA to keep alopecia therapy breakthrough tag
    Concert persuades FDA to keep alopecia therapy breakthrough tag

    15 Feb 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/concert-persuades-fda-keep-breakthrough-tag-alopecia-therapy-despite-lillys-arrival

    James Waldron FIERCE BIOTECH
    15 Feb 2023
    Share Share
    India's Sun Pharma acquires U.S. based Concert for $576 mln
    India's Sun Pharma acquires U.S. based Concert for $576 mln

    20 Jan 2023

    // REUTERS

    https://www.reuters.com/markets/deals/indias-sun-pharma-acquire-us-based-concert-576-mln-2023-01-19/

    REUTERS
    20 Jan 2023
    Share Share
    Concert Announces Presentation of Deuruxolitinib THRIVE-AA1 PIII Study Results
    Concert Announces Presentation of Deuruxolitinib THRIVE-AA1 PIII Study Results

    21 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221121005046/en

    BUSINESSWIRE
    21 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search